The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Advances in targeting histone deacetylase for treatment of solid tumors
Open accessAbstract
Histone deacetylase (HDAC) serves as a critical molecular regulator in the pathobiology of various malignancies and have garnered attention as a viable target for therapeutic intervention. A variety of HDAC inhibitors (HDACis) have been developed to target HDACs. Many preclinical studies have conclusively demonstrated the antitumor effects of HDACis, whether used as monotherapy or in combination treatments. On this basis, researchers have conducted various clinical studies to evaluate the potential of selective and pan-HDACis in clinical settings. In our work, we extensively summarized and organized current clinical trials, providing a comprehensive overview of the current clinical advancements in targeting HDAC therapy. Furthermore, we engaged in discussions about several clinical trials that did not yield positive outcomes, analyzing the factors that led to their lack of anticipated therapeutic effectiveness. Apart from the experimental design factors, issues such as toxicological side effects, tumor heterogeneity, and unexpected off-target effects also contributed to these less-than-expected results. These challenges have naturally become significant barriers to the application of HDACis. Despite these challenges, we believe that advancements in HDACi research and improvements in combination therapies will pave the way or lead to a broad and hopeful future in the treatment of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · cited 1×
“In general, HDACs exhibit distinct physiological functions and structural characteristics based on their respective classifications (Table 1) [23–26].”
BackgroundJiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30164-0 · Cited by 270
Self-citationSabnis, G. J., Goloubeva, O. G., Kazi, A. A., Shah, P., & Brodie, A. H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0345 · Cited by 74
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
Epigenetic regulation of key vascular genes and growth factors
Turunen, M. P., & Yla-Herttuala, S. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr109 · Cited by 41
Kong, Y., Ren, W., Fang, H., Shah, N. A., Shi, Y., You, D., Zhou, C., Jiang, D., Yang, C., Liang, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65322 · Cited by 25 · cited 1×
“This research unveils a new mechanism through which HDACis suppress basal-like breast cancer, highlighting an innovative interaction between KLF5 protein acetylation and ubiquitination [52].”
Background
Metadata
- Authors
- Shi, M.-Q., Xu, Y., Fu, X., Pan, D.-S., Lu, X.-P., Xiao, Y., & Jiang, Y.-Z.
- Venue
- Journal of Hematology & Oncology
- Published
- 2024-05-31
- Volume
- 17
- Issue
- 1
- Pages
- 37-37
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W4399205743
- Cited by
- 161
- References
- 8
- FWCI
- 18.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in targeting histone deacetylase for treatment of solid tumors. https://app.cochat.ai/papers/10.1186/s13045-024-01551-8
- The paper
- Shi, M.-Q., Xu, Y., Fu, X., Pan, D.-S., Lu, X.-P., Xiao, Y., & Jiang, Y.-Z. (2024). Advances in targeting histone deacetylase for treatment of solid tumors. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-024-01551-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.